RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)
In a report released yesterday, Douglas Miehm from RBC Capital maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a ...
Barclays Sticks to Its Buy Rating for Ligand Pharma (LGND)
Barclays analyst Balaji Prasad maintained a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $150.00.
Toronto Star22d
Opinion | Cultural appropriation isn’t the problem, it’s how the entrepreneurs advertise their product
If an Asian person were to make this same pitch, would there be a problem? People can improve a product without the cultural origin coming into question. Cultural origin does not define ownership ...
Yahoo Finance14d
Ligand Pharmaceuticals Incorporated (LGND)
After hours: 1 November at 16:03 GMT-4 ...